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INTRODUCTION
Breast cancer has become the most common female
cancer in many Asian and western developed countries.
The incidence of early-stage breast cancer is steadily
increasing and the risk of disease recurrence remains.
Risk evaluation and selection of adequate adjuvant treat-
ments are essential to reduce such recurrences. Because
most estrogen receptor (ER)-positive breast cancers are
dependent on estrogen for growth, ER-positive cancers
have been the target of adjuvant endocrine treatment.
Current primary strategies of adjuvant endocrine therapy
are inhibition of estrogen synthesis and ER antagonists
that block or destroy the ER. 
Adjuvant hormonal therapy is the first target-specific
approach for curing breast cancers due to its high efficacy
and mild side effects. Five years of tamoxifen therapy
has been the gold standard for women with ER-positive
breast cancer irrespective of age or menopausal and nodal
status.(1) However, its use has been challenged by the
emergence of 3rd generation aromatase inhibitors (AI).
At the St. Gallen Concensus Conference, five years of
either tamoxifen or tamoxifen plus ovarian function sup-
pression were proposed as acceptable standards for pre-
menopausal women while AIs were suggested as part
of standard endocrine therapy for the postmenopausal
women.(2) 
In order to maximize the efficacy and to minimize the
side effects of adjuvant hormonal therapy, it is important
to provide more detailed, improved, and individualized
therapeutic strategies. Therefore, in the current paper,
Adjuvant hormonal therapy is used as the first target-specific
approach in curing breast cancers due to its high efficacy
and mild side effects. Five years of tamoxifen therapy has
been the gold standard for women with estrogen receptor-
positive breast cancer irrespective of age or menopausal and
nodal status. After the emergence of 3rd generation aro-
matase inhibitors (AI), the use of either tamoxifen or tamox-
ifen plus ovarian function suppression for 5 years has been
proposed as an acceptable standard for premenopausal
women while AI should form part of standard endocrine
therapy for the postmenopausal women as established at
the St. Gallen Concensus Conference. The addition of
luteinizing-hormone-releasing hormone (LHRH) analogs
might be beneficial for the younger patients who remain
premenopausal after chemotherapy, however controversies
over the addition of LHRH analogs remains. Further, it has
been suggested that CYP2D6 polymorphisms and con-
comitant use of CYP2D6 inhibitors which reduce CYP2D6
activity may influence the clinical outcomes of adjuvant
tamoxifen therapy. The androgen receptor has been evalu-
ated as a prognostic or predictive marker for endocrine
responsiveness in a few studies; however, there are many
issues to be answered and ongoing clinical trials will provide
the answers. Until then, it would be important for clinicians
to carefully evaluate the risk factors of patients, monitor the
compliance of those patients who are under endocrine ther-
apy, and take care in selecting antidepressants when co-
prescription with tamoxifen is necessary. In the future, tailor-
ed therapy will be designed based on the target molecular
profiling of the tumors, pharmacogenomics, and improved
understanding of receptor signaling biology. More attention
should be given to explore molecular markers that could
differentiate the subsets for tailoring.
Key Words: Aromatase inhibitors, Breast Neoplasms, Hormonal antineoplastic
agents, Tamoxifen
Journal of
Breast 
Cancer
REVIEW ARTICLE
Adjuvant Hormonal Therapy: Current Standard and Practical Issues
Byeong-Woo Park, Hyung Seok Park
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Correspondence: Byeong-Woo Park 
Department of Surgery, Yonsei University College of Medicine,
134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea
Tel: 02-2228-2100, Fax: 02-313-8289
E-mail: bwpark@yuhs.ac 
Received: July 14, 2010   Accepted:September 2, 2010
242
J Breast Cancer 2010 September; 13(3): 242-9 DOI: 10.4048/jbc.2010.13.3.242
Adjuvant Hormonal Therapy 243
we have reviewed current standard and practical issues. 
ADJUVANT HORMONAL THERAPY FOR THE
POSTMENOPAUSAL BREAST CANCERS
Adjuvant hormonal therapy for postmenopausal breast
cancers is relatively simple. Tamoxifen, which targets
ER and AI which inhibit peripheral estrogen synthesis
are the two main therapeutic agents. Issues for post-
menopausal hormonal therapy involve whether to use
AI, optimal timing and duration of AI, and which AI is
the most effective. 
Tamoxifen or aromatase inhibitors
Although 5 yr of adjuvant tamoxifen therapy was shown
to significantly reduce the relative risk of recurrence by
41% and mortality by 34%,(1) 3rd generation AI showed
superiority over tamoxifen in terms of disease-free sur-
vival (DFS) in various clinical trials such as those exam-
ining upfront adjuvant use,(3,4) switch adjuvant setting,(5,
6) and extended adjuvant therapy.(7) However, only
switching to the use of anastrozole showed a significant
benefit in overall survival (OS) in a subsequent meta-
analysis.(8) Although a meta-analysis of the Arimidex,
Tamoxifen, Alone or in Combination (ATAC) and Breast
International Group (BIG) 1-98 up-front use of AI studies
revealed improved DFS but no significant difference in
ovarian function suppression relative to tamoxifen,(9)
the adjuvant use of AI reached consensus and became
the standard of adjuvant hormonal therapy for the post-
menopausal breast cancers except for in those patients
who are contraindicated to AI use or are of very low risk
of recurrence. 
Despite this standard, remaining issues such as timing
and duration of AI use, and the best AI to use did not
reach consensus. 
Timing of aromatase inhibitors
Since three different approaches such as upfront use,
switching, and extended use of AI demonstrated the super-
ior efficacy of AI over tamoxifen or placebo, The National
Comprehensive Cancer Network (NCCN) guidelines rec-
ommended all three approaches.(10)
Both the BIG 1-98(3) and ATAC(4) studies reported
improved DFS and time to distant recurrence in favor
of AI with no impact on OS. A meta-analysis of the BIG
1-98 and ATAC upfront studies also demonstrated that
AI reduced distant recurrence (hazard ratio [HR], 0.84;
p=0.009), with no significant improvement over tamox-
ifen on OS.(9) The BIG 1-98 study revealed a nonsignifi-
cant difference between letrozole montherapy and tamox-
ifen monotherapy with respect to OS (p=0.08), a result
which underestimates the survival benefit that would have
accrued if there had been no crossover to letrozole.(11)
Although the Austrian Breast and Colorectal Cancer
Study Group (ABCSG) 8 trial (sequential use of AI)(9,12)
did not show significant difference, a meta-analysis of
switch studies including Arimidex-Nolvadex 95 (ARNO
95) trial, the Italian Tamoxifen Arimidex (ITA) trial, the
Intergroup Exemestane Study (IES), and ABCSG-8 trial
showed that AI significantly improved both distant recur-
rence (HR, 0.76; p=0.01) and breast cancer mortality (p=
0.02).(9) 
To compare the upfront and sequential use of AI, BIG
1-98 data was analyzed at a median follow-up of 71
months,(11,13) Results demonstrated that there was no
statistically significant difference in DFS between five
years of treatment with letrozole versus the letrozole
followed by a tamoxifen sequence versus the tamoxifen
followed by a letrozole sequence. There was a nonsignifi-
cant increase in the risk of early relapse among women
with node-positive disease who were assigned to tamox-
ifen followed by letrozole and upfront letrozole for two
years followed by tamoxifen, yielding outcomes similar
to those seen with letrozole monotherapy.(11)
The National Cancer Institute of Canada Clinical Trials
Group MA.17 (MA.17) study randomized patients to receive
either five years of letrozole or placebo after completion
of five years of tamoxifen.(7) The trial was prematurely
unblended at 2.4 yr of follow-up because letrozole signif-
icantly improved DFS and OS compared with placebo.
The MA.17 study suggested a possible role of sustained
adjuvant endocrine therapy for the ER-positive breast
cancers with a long-term risk of relapse.
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Taken together, tamoxifen monotherapy for five years
seems to be suboptimal treatment in high-risk breast
cancer patients and upfront use of AI would at least be
beneficial for DFS. Since the risk of recurrence peaks early
at 1-3 yr after primary therapy,(14,15) and that most
patients with ER-positive cancers have a persistent risk
of recurrence, it would be reasonable to offer most post-
menopausal ER-positive cancer patients upfront use of
AI. On the contrary, patients who have already started
tamoxifen, should be advised to switch AI and patients
who have already completed five years of tamoxifen ther-
apy should consider the additional use of an AI.
Duration of aromatase inhibitors
The optimal duration of AI has not been determined.
The 100-month analysis of the ATAC trial demonstrated
a significantly larger carryover effect after five years of
anastrozole compared with tamoxifen.(4) However, it is
too early to say that five years of upfront AI use is enough.
Rather, the optimal duration of AI should be revealed
by the results of the ongoing rerandomizaton trial of the
MA.17R trial.
Which aromatase inhibitors?
There have been no results showing a direct comparison
between AI; however, the Femara versus Anastrozole
Clinical Evaluation (FACE) trial will compare the efficacy
of letrozole with anastrozole in node-positive patients(16)
and the MA.27 trial will compare the safety and efficacy
of the upfront use of anastrozole with exemestane.(17,18)
Until then, indirect comparison will have to suffice as a
point of reference. 
ADJUVANT HORMONAL THERAPY FOR
PREMENOPAUSAL BREAST CANCERS
Adjuvant hormonal therapy for the premenopausal
breast cancers is a little more complicated than in post-
menopausals, since premenopausal women have func-
tioning ovaries. Five years of tamoxifen use is the gold
standard for the ER-positive premenopausal breast can-
cers; however, the duration of tamoxifen therapy, the role
of ovarian function suppression, the duration of endocrine
therapy, and the use of AI is the issues yet to be resolved. 
Gold standard
The most recent Early Breast Cancer Trialists’Collabo-
rative Group (EBCTCG) Oxford Overview(1) confirmed
that five years of tamoxifen was associated with a signi-
ficant reduction in recurrence and mortality, extending
out to at least 15 yr after diagnosis. Therefore, tamox-
ifen has remained the gold standard for premenopausal
women since early 1980s. The panels of the 2009 St Gallen
Concensus Conference accepted five years of either
tamoxifen or tamoxifen plus ovarian function suppres-
sion as the standard endocrine therapy for premenopausal
women.(2)
Although tamoxifen is the gold standard of adjuvant
hormonal therapy for the premenopausal women with
breast cancers, chemotherapy has a key role in these
patients. A combination of chemotherapy and tamoxifen
has been demonstrated to be superior to either on their
own in premenopausal women with high-risk ER-posi-
tive breast cancers.
Duration of tamoxifen
Five years of tamoxifen has been confirmed as signif-
icantly more effective than two years, with further reduc-
tion in the annual recurrence and mortality.(1) Since the
National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-14 trial(19) demonstrated that more than five
years of tamoxifen was associated with a significantly
worse DFS, five years has remained as the optimal dura-
tion of tamoxifen administration. However, the NSABP B-
14 trial(19) included patients with ER-positive, node-nega-
tive, and those disease-free after five years of tamoxifen
and only 26% were younger than 50 yr of age. The benefit
of more than five years of tamoxifen in premenopausal
and postmenopausal women remains unclear(1) and there
may be a benefit to longer tamoxifen therapy in those
patients with node-positive disease.(20) Two large trials
of tamoxifen duration are still ongoing: the Adjuvant
Tamoxifen, Longer Against Shorter (ATLAS)(21,22) and
Adjuvant Treatment Tamoxifen to Offer More (aTTom)
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trials for the premenopausal and postmenopausal women,
respectively.(23,24) Both trials have shown some benefit
through preliminary analysis;(22,24) however, further
follow-up is required. Meanwhile, the optimal duration
of tamoxifen remains an open question until results can
confirm otherwise.
Addition of ovarian function suppression vs.
chemotherapy
Several trials comparing luteinizing-hormone-releasing
hormone (LHRH) analogs with chemotherapy as well as
the LHRH meta-analysis have shown no significant
difference in recurrence or death after recurrence.(25)
However, none of these trials included tamoxifen, and
therefore both arms were clinically suboptimal.
In the Oxford Overview, the efficacy of ovarian ablation
was almost entirely lost in the presence of chemother-
apy(1) and the addition of an LHRH agonist to chemother-
apy alone or to chemotherapy and tamoxifen did not
significantly reduce the risk of recurrence;(25) however,
there was a significant benefit in women younger than
40 yr of age. The Intergroup 0101 trial demonstrated
that no additional advantage with the addition of LHRH
agonist, but there was a significant improvement in DFS
and a nonsignificant trend to improved OS with the
addition of combined tamoxifen and LHRH agonist.(26)
There was also a trend for benefit with the addition of
LHRH agonist after chemotherapy in women younger
than 40 yr of age. All these results support that conclusion
that tamoxifen has an additional benefit to chemotherapy
and suggests that the addition of LHRH analogs would
be beneficial for younger patients who remains pre-
menopausal after chemotherapy.
Duration of ovarian function suppression?
The 2005 Oxford Overview demonstrated that there is
no significant difference in the efficacy between ovarian
ablation (OA) and OS and a trend against LHRH ana-
logs.(1)
The positive results of long-term estrogen suppression
in the postmenopausals shown in the MA.17 trial and a
trend against LHRH analogs shown in the 2005 Oxford
Overview raise the question of optimal duration for ovar-
ian ablation and whether LHRH analog treatment for 2-
3 yr is as effective as permanent ablation. 
Aromatase inhibitors for the pre- or 
peri-menopausal women
Aromatase inhibitors are contraindicated in women with
functioning ovaries because the suppression of peripheral
aromatase results in the reduced feedback of estrogen
to the hypothalamus and an increase in ovarian stimu-
lation,(27-30)which causes cystic changes in the ovary. 
Most women older than age 40 treated with chemother-
apy will develop permanent amenorrhea.(31,32)However,
Smith et al.(29) reported that the incidence of ovarian
function recovery was increased by the use of AI up to
27% compared with 0-11% spontaneously in women older
than 40.(31,33) Recovery of ovarian function has been
associated with the return of premenopausal estradiol
levels which would diminish or abolish the anticipated
anticancer efficacy, and can cause unwanted preg-
nancy.(29)
Based on the data, the use of AI should be performed
with caution in patients with chemotherapy-induced
amenorrhea, and it is important to regularly monitor
ovarian function in patients who are using AI after pre-
mature cessation of menstruation of chemotherapy.
Use of an AI after ovarian ablation or suppression is
theoretically possible; however, no data exists to indicate
the long-term effects of complete estrogen suppression
in young women. The ABCSG -12 study, which compared
the outcomes of ovarian function suppression in addition
to either anastrozole or tamoxifen, recently reported that
no significant difference in DFS was seen between two
arms with a median follow-up of 47.8 months.(34)Longer
follow-up results, two large IBCSG trials, and the SOFT
and TEXT trials(35) may provide clarity to this issue.
CYP2D6 POLYMORPHISM AND CYP2D6
INHIBITORS
Tamoxifen itself has low affinity to ER, meanwhile its
active metabolite forms, 4-hydroxytamoxifen and 4-
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hydroxy-N-desmethyltamoxifen (endoxifen) which are
mainly mediated by CYP2D6, are more potent than tamox-
ifen in their antiestrogenic effects.(36-39) Genetic poly-
morphisms of CYP2D6 can cause different CYP2D6 activity
and are known to be quite different among ethnic groups,
especially the CYP2D6*10 allele which is more commonly
observed in Asians,(40,41) as compared with the *4 allele
which is frequently observed in Caucasians.(42,43) 
Since a previous report suggesting that *4/*4 genotypes
tend to have a higher risk of disease recurrence,(44) a
few studies have reported that Asian patients carrying
homogenous *10 alleles are associated with a higher
hazard ratio or poorer survival results.(45-47) Okishiro
et al. suggested that CYP2D6*10/*10 genotype, which
was mainly related with the Intermediate Metabolizer
group, was not associated with prognosis in patients
treated with tamoxifen,(48) and recent meta-analysis
results could not demonstrate statistically significant
differences according to CYP2D6 genotyping in terms of
DFS and OS.(49)
Treatment with drugs that inhibit CYP2D6 may reduce
the clinical benefit of tamoxifen by interfering with its
bioactivation, particularly when these drugs are used for
an extended period. Antidepressants have been widely
prescribed in patients with breast cancer for treatment
of depression, tamoxifen- related hot flashes, and various
other indications.(50-53) Selective serotonin reuptake
inhibitor (SSRI) antidepressants inhibit CYP2D6 to varying
degrees. Paroxetine is an exceptionally potent CYP2D6
inhibitor, and is the only SSRI that exhibits mechanism
based (‘suicide’) inhibition, resulting in the irreversible
loss of enzyme function until new CYP2D6 can be syn-
thesized.(54-56)
Kelly et al.(57) reported that paroxetine use during
tamoxifen treatment was associated with an increased
risk of death from breast cancer. Based on such results,
when co-prescription of tamoxifen with an antidepressant
is necessary, preference should be given to antidepres-
sants that show little or no inhibition of CYP2D6.(57)
However, Dejentje et al.(58) did not show an association
between concomitant CYP2D6 inhibitor use and breast
cancer recurrence among patients treated with adjuvant
tamoxifen but rather, demonstrated that poor tamoxifen
adherence was associated with an increased risk of breast
cancer events. 
Although it is not clear whether CYP2D6 polymorphism
and CYP2D6 inhibitors are critically related to the tamox-
ifen efficacy, clinicians should be careful in choosing anti-
depressants. When co-prescription with tamoxifen is
necessary clinicians should also check the compliance of
tamoxifen ingestion during follow-up. 
ANDROGEN RECEPTOR EXPRESSION AS A
MARKER FOR ENDOCRINE RESPONSIVENESS
The role of the androgen receptor (AR) in breast cancer
has not yet been established. However, most authors
cite that 60-70% of tumors are AR positive, which is
comparable to or higher than that reported for ER and
progesterone receptor.(59,60) Limited studies have
demonstrated the role of AR as a prognostic factor and
the clinical implication of AR expression in ER-positive
breast cancer.(60) Further studies through both univariate
and multivariate analysis adjusting for age, tumor size,
nodal stage, and HER-2 status may give more information
about AR expression in luminal subtypes that may be
associated with survival outcomes.
CONCLUSION
Endocrine therapy is the key element in the manage-
ment of endocrine responsive breast cancers. Five years
of either tamoxifen or tamoxifen plus ovarian function
suppression have been proposed as acceptable standards
for premenopausal women, while AI should form part
of standard endocrine therapy for the postmenopausal
women. However, there are many issues to be answered
and ongoing clinical trials will provide the necessary
answers in the near future. Until then, it would be prac-
tical for clinicians to carefully evaluate the risk factors
of patients, monitor the compliance of patients who are
under endocrine therapy, and take care in choosing anti-
depressants when co-prescription with tamoxifen is nec-
essary. 
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In the future, tailored treatment will be applied based
on the target molecular profiling of the tumors, pharma-
cogenomics, and improved understanding of receptor
signaling biology. More attention should be given to
exploring molecular markers that could differentiate
the subsets for such tailoring.
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